Cancer News and Research

Latest Cancer News and Research

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

5 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

Micromet second-quarter 2010 total revenues increase to $6.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

New study reinforces need for national catastrophic drug plan in Canada for cancer patients

In a newly released report comparing international usage of prescription drugs, Canada ranks thirteenth among 14 countries for cancer drugs launched within the last five years. The study, conducted for the UK Secretary of State for Health, compared 14 countries for their usage of 14 categories of prescription drugs to determine whether the UK is adequately providing for the health needs of its citizens.

5 Aug 2010

Cord Blood America strengthens balance sheet by reducing financial obligations

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that it has had positive movement on two financial obligations that further strengthen its balance sheet.

5 Aug 2010

Stand Up To Cancer movement unveils display window in Rockefeller Plaza

Stand Up To Cancer, a groundbreaking movement that has raised more than $100 million for accelerated cancer research, today unveiled a 115-square foot display window in 10 Rockefeller Plaza, created to generate tune-in for the upcoming Stand Up To Cancer television event, set to air live for one hour, commercial-free in primetime on September 10, 2010, at 8p.m. EDT & PDT / 7 p.m. CDT.

5 Aug 2010

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Scientists discover gene linked to eight-fold risk of breast cancer recurrence

Cancer Research UK scientists have discovered that a gene called POLQ is linked to an eight-fold risk of breast cancer returning. Developing drugs to block POLQ could increase survival and stop the cancer coming back, according to research published in OncoTarget.

5 Aug 2010

CEL-SCI produces and fills first lot of Multikine

CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.

5 Aug 2010

Primary care practices recognized with Priority Health Quality Awards

Priority Health, one of the nation's top health plans, is pleased to recognize 138 primary care practices across the state of Michigan with the Priority Health Quality Awards. The Priority Health Quality Awards were established in 2003 to recognize excellence in health care. Quality Awards are presented in two categories: Exceptional Patient Care and Outstanding Health Care Value. Among the honorees are 38 practices winning awards in both categories.

5 Aug 2010

Gene associated with susceptibility to chronic pain caused by nerve injury identified

Researchers at the Hebrew University of Jerusalem and elsewhere have succeeded in identifying for the first time a gene associated with susceptibility to chronic pain caused by nerve injury in humans, signalling a significant step toward better understanding and treating of the condition.

5 Aug 2010

Genomic sequence of living marine sponge reveals some basic information about cancer: Scientists

This week's publication of the complete genomic sequence of a living marine sponge reveals genes dating back hundreds of millions of years -- a result far exceeding the expectations of the scientific world.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

CTI second-quarter total net operating expenses decrease to $20.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the second quarter ended June 30, 2010.

5 Aug 2010

ARIAD reports $159.3 million second-quarter net income

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

5 Aug 2010

Bionovo reports total revenue of $14,000 for second-quarter 2010

Bionovo, Inc. today announced second quarter highlights and financial results for the three months ended June 30, 2010.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

TapImmune inks smallpox vaccine Research and Technology License Option Agreement with Mayo Clinic

TapImmune Inc. announced that it has signed a Research and Technology License Option Agreement with Mayo Clinic, Rochester, MN, for the development of a smallpox vaccine technology. Research will be conducted by Gregory Poland M.D., at Mayo Clinic, to evaluate novel peptide antigens together with TapImmune's proprietary TAP technology. TapImmune also has an exclusive Option to the smallpox vaccine technology after research studies have been completed under the terms of the agreement.

5 Aug 2010

Cancer News and Research

Latest Cancer News and Research

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Incyte second-quarter total revenues increase to $49.8 million

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Micromet second-quarter 2010 total revenues increase to $6.5 million

New study reinforces need for national catastrophic drug plan in Canada for cancer patients

Cord Blood America strengthens balance sheet by reducing financial obligations

Stand Up To Cancer movement unveils display window in Rockefeller Plaza

BioCryst second-quarter total revenues increase to $7.6 million

Scientists discover gene linked to eight-fold risk of breast cancer recurrence

CEL-SCI produces and fills first lot of Multikine

Primary care practices recognized with Priority Health Quality Awards

Gene associated with susceptibility to chronic pain caused by nerve injury identified

Genomic sequence of living marine sponge reveals some basic information about cancer: Scientists

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

CTI second-quarter total net operating expenses decrease to $20.0 million

ARIAD reports $159.3 million second-quarter net income

Bionovo reports total revenue of $14,000 for second-quarter 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

TapImmune inks smallpox vaccine Research and Technology License Option Agreement with Mayo Clinic

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in